시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계 세포 및 유전자 치료 시장 보고서(2024년)
Cell and Gene Therapy Global Market Report 2024
상품코드 : 1429361
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,000 ￦ 7,454,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,500 ￦ 11,181,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 ￦ 14,908,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세포 및 유전자 치료 시장 규모는 향후 수년간 지수적으로 성장할 것으로 예상됩니다. 2028년 복합 연간 성장률(CAGR) 23.1%를 나타낼 전망이며 397억 4,000만 달러로 성장할 것으로 예상됩니다. 예상되는 성장은 암과 만성 질환의 유병률 증가, 노인 인구 증가, 세포 및 유전자 치료에 대한 관심 증가, 건강 관리 비용 증가로 촉진됩니다. 주요 동향으로는 CAR T 세포 요법과 같은 고급 치료법, 조사 이니셔티브, 전략적 제휴, CRISPR과 같은 유전자 편집 도구의 중요성, 제휴 또는 인수, 세포 및 유전자 치료를위한 파이프라인 연구 확대, 제조 시설 확장에 대한 투자가 포함됩니다.

세포 및 유전자 치료(CGT) 시장의 성장은 섹터 내에서 일관된 투자와 통합 노력에 의해 크게 촉진되었습니다. CGT 시장의 엄청난 잠재력을 인식하고 매출 랭킹 상위 20개 바이오의약품 기업 중 16개가 CGT 제품을 자체 포트폴리오에 통합하고 있습니다. 알기 쉬운 예로, 화이자는 2021년 12월 노스캐롤라이나주 더럼에 최첨단 시설을 설립하기 위해 6,850만 달러라는 많은 투자를 할당했습니다. 이 전략적 조치는 회사의 유전자 치료 능력을 더욱 향상시키는 것을 목표로 했습니다. 노스캐롤라이나 주에서 화이자의 시설 확장은 주 내 여러 기지에서 3,600명이 넘는 직원을 수용하고 유전자 치료에서 종단 간 능력을 강화하는 데 크게 기여하고 있습니다. 꾸준한 투자 유입과 CGT 생산 능력의 통합은 생산 능력을 증대시켜 시장 성장을 가속하고 있습니다.

현재 진행중인 임상시험의 급증이 세포 및 유전자 치료 시장을 전진시키는 원동력이 되고 있습니다. 임상시험은 새로운 치료법, 개입 또는 진단 절차의 안전성과 효능을 평가하기 위해 인간 참가자가 관여하는 매우 중요한 조사 연구 역할을 합니다. 세포 및 유전자 치료 영역에서 이러한 시험은 안전성과 효능을 평가하기 위한 통제된 환경을 제공함으로써 혁신적인 치료법의 진보에 필수적인 역할을 합니다. 국립위생연구소(NIH)의 부문인 ClinicalTrials.gov의 데이터로 입증된 바와 같이, 등록된 연구의 수는 2022년 437,523건에서 2023년 10월까지 미국 50개 주 모두 221개국에 걸쳐 468,457건으로 크게 증가했습니다. 주목할 만하게, 이들 연구의 상당 부분(전체의 31%)인 143,613건은 미국 내에서만 실시되고 있는 반면, 251,159건의 연구(전체의 54%)는 미국 이외의 장소에서 실시됩니다. 이 진행 중인 임상시험 수 증가는 세포 및 유전자 치료 시장의 성장 궤도의 원동력이 되는 것을 알 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

제5장 세계 시장 규모와 성장

제6장 시장 세분화

제7장 지역 및 국가 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 선도적이고 혁신적인 기업

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 미래 전망과 가능성 분석

제36장 부록

BJH
영문 목차

영문목차

Gene therapy involves delivering genetic material, typically through a carrier or vector, with the gene being taken up by the appropriate body cells. Cell therapy, on the other hand, entails introducing cells into the patient to restore proper function. Some procedures combine both cell and gene therapy.

The primary product categories in cell and gene therapies are cell therapy and gene therapy. Gene therapy in medicine focuses on modifying the genetic material of cells for therapeutic effects or disease healing by repairing damaged genetic material. Applications span oncology, dermatology, musculoskeletal treatments, and others, with utilization across sectors such as hospitals, ambulatory surgical centers, cancer care centers, wound care centers, and more.

The cell and gene therapy market research report is one of a series of new reports from The Business Research Company that provides cell and gene therapy market statistics, including global market size, regional shares, competitors with a cell and gene therapy market share, detailed cell and gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy industry. This cell and gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cell & gene therapy market size has grown exponentially in recent years. It will grow from $13.81 billion in 2023 to $17.31 billion in 2024 at a compound annual growth rate (CAGR) of 25.3%. The historical growth can be attributed to an increase in investments in cell and gene therapies, growth in research and development, advances in cancer drug discovery, a rise in public-private partnerships, strong economic growth in emerging markets, increased healthcare expenditure, and an increase in pharmaceutical R&D expenditure.

The cell & gene therapy market size is expected to see exponential growth in the next few years. It will grow to $39.74 billion in 2028 at a compound annual growth rate (CAGR) of 23.1%. Forecasted growth is fueled by increasing cancer and chronic disease prevalence, a growing geriatric population, heightened focus on cell and gene therapy, and rising healthcare expenditure. Key trends include advanced therapies such as CAR T-cell therapy, research initiatives, strategic collaborations, emphasis on gene editing tools such as CRISPR, partnerships or acquisitions, expanded pipeline studies for cell and gene therapies, and investment in manufacturing facility expansion.

The growth of the cell and gene therapy (CGT) market has been significantly bolstered by consistent investment and consolidation initiatives within the sector. Recognizing the immense potential of the CGT market, 16 of the top 20 largest biopharmaceutical companies, ranked by revenue, have integrated CGT products into their portfolios. An illustrative example is Pfizer, which, in December 2021, allocated a substantial investment of $68.5 million to establish a cutting-edge facility in Durham, North Carolina. This strategic move aimed to further advance the company's gene therapy capabilities. Pfizer's facility expansion in North Carolina, accommodating over 3,600 employees across multiple sites in the state, significantly contributes to enhancing their end-to-end capabilities in gene therapy. The steady influx of investment and consolidation in CGT production capacity has resulted in an augmented production capacity, consequently fueling the market's growth.

The burgeoning number of ongoing clinical trials stands as a driving force propelling the cell and gene therapy market forward. Clinical trials serve as pivotal research studies involving human participants to assess the safety and efficacy of new medical treatments, interventions, or diagnostic procedures. In the realm of cell and gene therapy, these trials play an integral role in advancing these innovative therapies by providing a controlled environment to evaluate their safety and efficacy. As evidenced by data from ClinicalTrials.gov, a division of the National Institutes of Health (NIH), the number of registered studies increased significantly from 437,523 in 2022 to 468,457 across all 50 states of the United States and spanning 221 countries by October 2023. Notably, a considerable portion of these studies-143,613 (31% of the total)-are conducted solely within the U.S., while 251,159 studies (54% of the total) are conducted in non-U.S. locations. This escalating number of ongoing clinical trials signifies a driving force behind the growth trajectory of the cell and gene therapy market.

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a pivotal driver shaping the landscape of the cell and gene therapy (CGT) market. This innovative therapy combines elements of both cell and gene therapy by utilizing T cells obtained from a patient's blood, which are then genetically modified to produce specialized receptors known as chimeric antigen receptors (CARs) on their surface. These engineered T cells, equipped with modified receptors, are reintroduced into the patient's system. The modified receptors on the T cells enable them to effectively target and bind to specific surface antigens present on cancer cells, ultimately leading to the destruction of tumor cells within patients. A notable example occurred in June 2022 when Bristol-Myers Squibb Company, a US-based pharmaceutical firm, received approval from the United States Food and Drug Administration (US FDA) for Breyanzi, a CAR T cell therapy designed for treating adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma. Breyanzi stands out as a distinct CAR T cell therapy engineered from a patient's own T cells, collected and genetically reengineered into CAR T cells, subsequently administered via infusion as a one-time treatment.

Major companies operating within the cell and gene therapy market are intensifying their focus on introducing agnostic systems to gain a competitive edge. Agnostic systems encompass platforms integrated with a diverse array of cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. For instance, in April 2023, AmerisourceBergen, a US-based healthcare company, unveiled the Cell and Gene Therapy Integration Hub-a newly launched platform-agnostic system. This innovative system aims to enhance connectivity throughout the cell and gene therapy treatment journey, elevating the overall patient and provider experience. Powered by the company's customer relationship management system, the hub is designed to expedite the benefits investigation process, offer real-time insights into therapy development and transportation status, and assist in streamlining patient support coordination.

In December 2021, Novartis AG, a Switzerland-based pharmaceutical company, completed the acquisition of Gyroscope Therapeutics Holdings plc for $800 million. This strategic move adds GT005, an experimental one-time gene therapy in Phase 2 for treating geographic atrophy (GA), to Novartis' portfolio. The acquisition enhances gene therapy research capabilities and contributes to global ophthalmic innovation for treating and preventing blindness. Gyroscope Therapeutics Holdings plc is a UK-based clinical-stage biopharmaceutical company specializing in gene therapies for eye-related diseases.

Major companies operating in the cell and gene therapy market report are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc., Mitsubishi Tanabe Pharma, Oxford Biomedica PLC, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma PLC, and AstraZeneca.

North America was the largest region in the cell and gene therapy market in 2023. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cell and gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The cell and gene therapy market includes revenues earned by entities treating cancer, cystic fibrosis, heart disease, diabetes, haemophilia, and AIDS. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cell and Gene Therapy Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cell and gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cell and gene therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cell and gene therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Scope

Markets Covered:

Table of Contents

1. Executive Summary

2. Cell and Gene Therapy Market Characteristics

3. Cell and Gene Therapy Market Trends And Strategies

4. Cell and Gene Therapy Market - Macro Economic Scenario

5. Global Cell and Gene Therapy Market Size and Growth

6. Cell and Gene Therapy Market Segmentation

7. Cell and Gene Therapy Market Regional And Country Analysis

8. Asia-Pacific Cell and Gene Therapy Market

9. China Cell and Gene Therapy Market

10. India Cell and Gene Therapy Market

11. Japan Cell and Gene Therapy Market

12. Australia Cell and Gene Therapy Market

13. Indonesia Cell and Gene Therapy Market

14. South Korea Cell and Gene Therapy Market

15. Western Europe Cell and Gene Therapy Market

16. UK Cell and Gene Therapy Market

17. Germany Cell and Gene Therapy Market

18. France Cell and Gene Therapy Market

19. Italy Cell and Gene Therapy Market

20. Spain Cell and Gene Therapy Market

21. Eastern Europe Cell and Gene Therapy Market

22. Russia Cell and Gene Therapy Market

23. North America Cell and Gene Therapy Market

24. USA Cell and Gene Therapy Market

25. Canada Cell and Gene Therapy Market

26. South America Cell and Gene Therapy Market

27. Brazil Cell and Gene Therapy Market

28. Middle East Cell and Gene Therapy Market

29. Africa Cell and Gene Therapy Market

30. Cell and Gene Therapy Market Competitive Landscape And Company Profiles

31. Cell and Gene Therapy Market Other Major And Innovative Companies

32. Global Cell and Gene Therapy Market Competitive Benchmarking

33. Global Cell and Gene Therapy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Cell and Gene Therapy Market

35. Cell and Gene Therapy Market Future Outlook and Potential Analysis

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기